Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 478 participants.
Also called NCT05950516
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 478 participants
- Registry
-
NCT05950516
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05950516. Randomized; no masking; primary purpose treatment. Start 2023-07-10 (anticipated); primary completion 2024-11-24 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Semaglutide Pen Injector [Ozempic]
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05950516- Content hash
db6869a134e79b72e85c4948c9cef2ec791518ddb55458f4107de0787fdfc3a7